MedPath

Reducing AIR Pollution Exposure to Lower Blood PRESSURE Among New York City Public Housing Residents

Not Applicable
Recruiting
Conditions
Blood Pressure
Interventions
Device: Active PAC
Device: Sham PAC
Registration Number
NCT05874479
Lead Sponsor
NYU Langone Health
Brief Summary

Fine particulate matter \<2.5 µm (PM2.5) air pollution is the fifth leading risk factor for global mortality, with the largest portion of deaths due to cardiovascular disease (CVD). While several mechanisms are responsible, PM2.5-induced elevations in blood pressure (BP) may be relevant. Indoor portable air cleaners (PACs) are a novel approach to reduce exposure to PM2.5 and potentially lower blood pressure. The current study is being conducted to provide evidence that PACs reduce PM2.5 exposure and lower systolic blood pressure (SBP) in key patient populations.

Detailed Description

Not available

Recruitment & Eligibility

Status
RECRUITING
Sex
All
Target Recruitment
440
Inclusion Criteria
  • self-reported nonsmokers living in a nonsmoking household.
  • adults living with hypertension (HTN) from NYC public housing.
Exclusion Criteria
  • History of major known arrhythmias (e.g. atrial flutter or fibrillation, ventricular tachycardia).
  • Screening systolic BP ≥160 mm Hg or diastolic BP ≥100 mm Hg (i.e. severe hypertension by the 2017 ACC/AHA BP guideline).
  • A change in drug regimen in the prior 2 weeks or a planned change in drug regimen during the first 30 days for those taking antihypertensive medication.
  • Current smoking or living with an active smoker who smokes indoors
  • Planned travel out of NYC for ≥2 weeks in next 6 months
  • Incarcerated
  • Pregnant
  • Unable/unwilling to consent
  • Established cardiovascular disease
  • End-stage renal disease (chronic kidney disease stage IV or on dialysis)
  • Barrier to technology use (e.g., visual or hearing impairment)
  • Lung disease requiring oxygen
  • Cancer receiving treatment

Study & Design

Study Type
INTERVENTIONAL
Study Design
PARALLEL
Arm && Interventions
GroupInterventionDescription
Active Portable Air Cleaner (PAC)Active PACUsing a double-blind randomized process, active PACs (with HEPA filters inside) will be assembled and placed in the bedroom of study participants. Initiation of the PAC devices will occur at baseline on Day 0. After completion of enrollment, consent and the placement of PACs, electricity monitors, and PurpleAir monitoring, the PAC will be turned on. Participants will be instructed to keep the PACs on in bedrooms during the study duration, closing bedroom doors at night and during the day, when possible. The PAC will run for 24 hours on Day 0 of the study protocol before the 30-day treatment period begins. A kilowatt meter will be installed with the PAC to monitor electricity usage as a measure of adherence.
Sham PACSham PACUsing a double-blind randomized process, sham PACs (with no filters inside) will be assembled and placed in the bedroom of study participants. Initiation of the PAC devices will occur at baseline on Day 0. After completion of enrollment, consent and the placement of PACs, electricity monitors, and PurpleAir monitoring, the PAC will be turned on. Participants will be instructed to keep PACs on in bedrooms during the study duration, closing bedroom doors at night and during the day, when possible. The PAC will run for 24 hours on Day 0 of the study protocol before the 30-day treatment period begins. A kilowatt meter will be installed with the PAC to monitor electricity usage as a measure of adherence.
Primary Outcome Measures
NameTimeMethod
Average Self-Measured Morning Home Systolic Blood Pressure (AM H-SBP) over 30 DaysUp to Day 30

Participants measure HBP every day between 6-9 am.

Secondary Outcome Measures
NameTimeMethod
Average Self-Measured Morning Home Systolic Blood Pressure (AM H-SBP) over 90 DaysUp to Day 90

Participants measure HBP every day between 6-9 am.

Average Self-Measured Morning Home Systolic Blood Pressure (AM H-SBP) over 180 DaysUp to Day 180

Participants measure HBP every day between 6-9 am.

Trial Locations

Locations (1)

NYU Langone Health

🇺🇸

New York, New York, United States

© Copyright 2025. All Rights Reserved by MedPath